))
Pragmatica-Lung Tests a Treatment and a New Approach to Trials
Manage episode 407462004 series 3560609
Content provided by Jacqueline Stone and OBR Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jacqueline Stone and OBR Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The newly opened Pragmatica-Lung trial compares ramucirumab plus pembrolizumab versus usual care for treatment of stage IV or recurrent non-small cell lung cancer. The trial is designed to ease enrollment requirements and data collection needs, focusing on the key endpoint of overall survival. Listen as study lead Karen Reckamp, MD, professor and division director for Cedar Sinai Cancer and Medical Oncology, and Bob Figlin, MD, the Steven Spielberg Family Chair in hematology oncology at Cedar Sinai Cancer, talk about how the trial came about and why it could change how future studies are done across cancer types
111 episodes
Share
